证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 ? Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产 （以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁项下， 公司将为 Vernalis 按照《复归租约》的约定支付所有款项及义务提供担保（以下 简称"本次担保 ...

Core Viewpoint - The Hong Kong stock market's biotechnology sector is experiencing a resurgence, with Baiaosaitu (02315) emerging as a standout performer due to its unique dual business model of "innovative animal models + antibody molecule transfer," leading to a significant increase in its stock price and valuation [1] Group 1: Innovative Animal Models - Baiaosaitu has established a strong foundation in innovative animal models, developing over 3,500 gene-edited animal and cell models, with more than 1,000 used for drug evaluation [2] - The company has transitioned from a service-oriented model to a product sales model, significantly enhancing drug development efficiency for innovative pharmaceutical companies [2] - In 2024, revenue from innovative animal models is projected to reach 389 million yuan, a 43% increase from 2023, with a three-year compound growth rate of approximately 52% and a gross margin exceeding 75% [3][4] Group 2: Antibody Transfer Development - The antibody discovery business has rapidly developed into a key growth driver for Baiaosaitu, with the "Thousand Mice Ten Thousand Antibodies" initiative aimed at large-scale drug development for over 1,000 potential drug targets [5][6] - By the end of 2024, Baiaosaitu had signed approximately 200 cooperation agreements for antibody molecule development, with seven of the top ten global pharmaceutical companies as clients [7] - Revenue from the antibody business is expected to reach 318 million yuan in 2024, an 81% increase from 2023, with a three-year compound growth rate of nearly 58% and a gross margin exceeding 80% [8] Group 3: Financial Performance and Valuation - In 2024, Baiaosaitu achieved total revenue of 980 million yuan, a year-on-year increase of approximately 37%, while maintaining a gross margin of around 78% [9] - The company reported a net profit of 33.54 million yuan, marking a turnaround from previous losses, and generated a net cash inflow from operating activities of 211 million yuan [9] - The unique dual-driven model of "innovative animal models + antibody transfer development" positions Baiaosaitu favorably in the market, leading to a higher valuation compared to peers [10]

Core Viewpoint - The traditional drug development model faces multiple challenges such as low efficiency, long cycles, and high failure rates, while AI is deeply reshaping the paradigm of biopharmaceutical research. However, the lack of structured, high-quality, and reusable research data resources severely restricts the value of AI algorithms in new drug development [1] Group 1: Challenges in Biomedicine - Current biomedical research in China faces challenges including a late start in data-intensive research, a lack of quality data resources, and high barriers to algorithm innovation and tool integration, which do not meet the needs for rapid modeling, precise prediction, and target identification under AI [2] - There is a disconnection between positive genetic data from humans and reverse genetic research from model organisms, preventing effective utilization of research resources [2] Group 2: AI and Phenotypic Data - Human phenotypic data and model organism phenotypic data are key nodes connecting "gene-phenotype-disease" and provide a real biological basis for AI algorithms to achieve mechanism modeling and target prediction [2] - The establishment of high-quality platforms for phenotypic data and model organisms will play an increasingly important role in the future, producing data for model training as demand increases [4] Group 3: Institutional Initiatives - Fudan University is building a resource library for experimental mice, integrating all animal facilities and planning to establish an online database for easier access [3] - The Bio-OS intelligent biological analysis tool developed by the Guangzhou National Laboratory team aims to address issues faced by researchers in data analysis, such as high development thresholds and low reusability [4] Group 4: Collaboration and Standardization - South Model Biology is collaborating with the Shanghai International Human Phenotype Group to explore standardization in phenotypic data analysis and ensure the provision of high-quality phenotypic data [4] - A proposal was made to establish "Shanghai Gene Engineering Mouse Experiment Standards" to unify model genetic backgrounds and phenotypic data collection standards [4] Group 5: Expert Participation - The seminar gathered authoritative experts and industry representatives from the fields of gene editing, phenomics, and AI computing, including professors and researchers from Fudan University and South Model Biology [5]

Core Viewpoint - The innovation speed and cost-effectiveness of Chinese biopharmaceutical companies have surpassed that of American companies, leading to a surge in stock prices for several Chinese biopharma firms [1][2]. Group 1: Market Performance - On June 9, 2023, Chinese biopharmaceutical companies saw a collective stock price increase, with Kelun-Botai (6990.HK) rising nearly 6% to a market cap exceeding HKD 80 billion, BeiGene (688235.SH) up over 8%, and Junshi Biosciences (688180.SH) up over 5% [1]. - The optimism surrounding original drug licensing contributed to the stock price increases, particularly following data presentations from Chinese companies at the recent ASCO annual meeting [1]. Group 2: International Interest - In recent months, American and European pharmaceutical companies have invested billions in acquiring Chinese-developed drugs, yielding returns for these companies [2]. - During the ASCO conference, BioNTech's resale of a tumor dual-antibody drug acquired from China's Pumice Biotech for over USD 10 billion to Bristol-Myers Squibb (BMS) highlighted the market's excitement [2]. - BMS is betting on a dual-antibody drug targeting PD-L1 and VEGF for treating various solid tumors, which shows potential to replace Merck's leading cancer drug, Keytruda [2]. Group 3: Competitive Landscape - The valuation of Chinese innovative drugs is considered reasonable by multinational companies, as they seek products with patent protection for lifecycle management [4]. - China has surpassed the U.S. in the number of clinical trials and has seen a significant increase in patent filings, attracting multinational pharmaceutical companies [4]. - AstraZeneca announced a USD 2.5 billion investment to establish a research center in Beijing, reflecting the growing interest in China's biopharmaceutical sector [4]. Group 4: Innovation and Development - Chinese biopharmaceutical companies have made rapid advancements in innovation over the past decade, although they still have a long way to go in achieving "original innovation" [4]. - The PD-L1/VEGF dual-antibody drug represents a significant innovation compared to traditional combination therapies, offering easier administration and potential cost reductions [4]. - Local companies like Kelun-Botai and InnoCare Pharma are actively investing in the development of antibody-drug conjugates (ADCs) in the competitive oncology market [4]. Group 5: Clinical Achievements - On June 6, 2023, Kelun-Botai's ADC drug, SKB264, received approval from the National Medical Products Administration (NMPA) and became the first TROP2 ADC drug approved for lung cancer indications globally [5]. - InnoCare Pharma presented data at ASCO indicating that its HER3-targeting ADC drug has potential comparable to Kelun-Botai's SKB264 for treating EGFR-resistant non-small cell lung cancer [5].

Core Insights - Jinan Rural Commercial Bank's "Talent Loan" project has been recognized as one of the "Top Ten Leading Demonstration Projects in Science and Technology Finance" in Jinan, showcasing its innovative financial support for technology and talent [1] - The bank focuses on providing financial support for technology innovation, green development, rural revitalization, small and micro enterprises, and livelihood security [1] - The bank has established a comprehensive talent financial service system, including various loan products tailored for technology-driven enterprises [3] Group 1: Talent Loan Impact - The "Talent Loan" has been crucial for companies like Shandong Aikeda Biotechnology Co., which received 9.5 million yuan in just five working days to support its operations and enhance its brand influence in the global diagnostics industry [2] - The financial support from Jinan Rural Commercial Bank has enabled companies to overcome funding challenges associated with high R&D costs and operational expenses [2] Group 2: Innovative Financing Solutions - Jinan Rural Commercial Bank offers a combination financing solution of "Talent Loan + Intellectual Property Pledge Loan," which has helped companies like Shandong Haiguan New Energy Technology Co. to resolve financing difficulties and reduce costs by 40% through government subsidies [3] - The bank's initiatives have led to significant growth for supported companies, with one reporting a 120% increase in output and over 30 million yuan in new orders in the past six months [3] Group 3: Collaborative Development - The establishment of a "Talent Loan Financial Service Window" in Jinan High-tech Zone aims to streamline financial services for high-level talents, ensuring optimal rates and efficient service [4] - The bank has integrated its services with the Jinan Talent Center and the "Jinan Talent" app, providing dedicated financial service channels for high-level talents [4][5] - As of April, the bank has issued 2.022 billion yuan in specialized support loans, expanding its coverage for technology innovation enterprises and key entrepreneurial groups [5]

Group 1 - The import of over 70 plasma standards by Hangzhou Chain Kang Medical Laboratory from Sweden was expedited through a joint regulatory mechanism established by the Hangzhou government and customs [1] - The demand for imported human plasma and serum for research in the biopharmaceutical industry is increasing due to its rapid development [1] - The joint regulatory mechanism has significantly reduced the time required for importing high-risk special items, allowing companies to focus on their research and development [2] Group 2 - The establishment of a cross-departmental task force by Qianjiang Customs and the Free Trade Zone management office provides one-on-one support for companies in preparing import materials [2] - Chain Kang Medical successfully became a "white list" enterprise under the joint regulatory mechanism, which helps in recovering critical research timelines [2] - Seven biopharmaceutical companies in Hangzhou have obtained "white list" status under the joint regulatory mechanism, enhancing their operational efficiency [2] Group 3 - The Hangzhou Customs plans to continue exploring new measures for "one-stop" customs clearance for special biopharmaceutical items, aiming to extend the joint regulatory mechanism to advanced fields like cell therapy and genetic testing [3] - From January to April, the import value of biological products in Hangzhou reached 150 million yuan, a year-on-year increase of 11.4%, accounting for 84.2% of the total biological product imports in Zhejiang Province [3]

Core Viewpoint - Shenzhen is implementing a comprehensive plan to promote high-quality development in service trade and digital trade, aiming to enhance its international competitiveness and establish itself as a global economic center by 2030 and 2035 [1]. Group 1: Promotion of Efficient Flow of Trade Resources - The plan focuses on four key areas: facilitating cross-border data flow, accelerating technology transfer, providing financial support for trade development, and enabling talent mobility [2]. - A pilot "negative list" system for cross-border data flow will be established in specific regions, allowing approved research institutions and enterprises to share scientific data securely [2]. - The initiative includes expanding the use of the Renminbi in cross-border transactions and improving the efficiency of its use in various financial activities [2]. Group 2: Innovation in Digital Trade - The plan aims to attract foreign investment in telecommunications and internet services, enhancing the overall scale and competitiveness of the software and information services industry [3]. - Support will be provided for the development of original digital products with independent intellectual property rights, focusing on improving technology content and user experience [3]. - The initiative encourages the use of advanced digital technologies to upgrade service industries, promoting innovation in digital services such as digital finance and online education [3]. Group 3: Enhancement of Service Trade - The plan includes measures to improve international transportation services and expand shipping routes to various regions, including Europe and Africa [6]. - It aims to attract high-level international medical resources and professional service institutions to establish a presence in Shenzhen [6]. - The initiative also seeks to develop cross-border financial and insurance services, enhancing the efficiency of cross-border fund settlement for e-commerce enterprises [6]. Group 4: Support for Digital and Smart City Services - The plan encourages the export of digital and smart city services to markets in ASEAN, the Middle East, Latin America, and Southern Europe [7]. - It aims to facilitate cross-border travel services and support foreign-invested travel agencies in conducting outbound tourism business [7]. - The initiative promotes the development of high-value-added bonded maintenance services and the establishment of a global trading center for electronic components [7].

5月27日，在石家庄市国际生物医药园中央创新区，石家庄诺澳原生物技术有限公司技术人员在使用共 享实验室设备进行研发。本报见习记者 冯依凡摄 药物研发，实验室是各单位的关键阵地。而在石家庄，有个实验室，向药企、科研院所等敞开大门，这 是咋回事？ 来源：河北日报 5月27日，记者前往石家庄市国际生物医药园中央创新区共享实验室，一探究竟。 在位于3楼的共享实验室内，80套总价值千万元的仪器设备整齐排列。走廊两侧墙壁上，张贴着正置显 微镜、倒置显微镜、高效液相色谱仪等设备图片与操作指南。 在共享实验室一角，工人们正忙着搬运设备、调试线路。 "这是一场无缝衔接的创新接力。"园区运营商石家庄鹏泰置业投资有限公司副总经理李茹说，石家庄诺 澳原生物技术有限公司刚从这里搬到5楼定制办公区，河北医大一院的专家团队就火速接棒入驻，园区 正为他们升级细胞研发平台。 受益于共享实验室的，除了初创团队、科研院所，还有生物医药骨干企业。 前段时间，华普石家庄医药有限公司研发人员在共享实验室驻扎了半个月。"多亏这里的PCR（聚合酶 链式反应）测试仪，我们完成关键指标检测，加快了研发进程。"该公司质量总监陈会珍说，共享实验 室就像"超级武器库 ...

项目签约、成果发布、代表发言……5月29日，2025浙江.台湾合作周温州专场活动在浙江温州启幕。本 次温州专场活动以"共育新质生产力.共享开放新机遇"为主题，精心策划了"1+4"系列活动框架。温州人 素以"敢为天下先"闻名，台湾人有"爱拼才会赢"的精神。近300位来自海峡两岸的嘉宾、专家学者、行 业协会成员、企业代表及在温台商台青共聚一堂，携手探索新质生产力的发展路径，共绘温台各领域融 合发展的新篇章。 海峡两岸(温州)大健康产业园自启动以来，已形成一定的产业集聚效应，尤其在生物医药研发、医疗服 务体系建设等方面，具备开展深度合作的广阔空间。今年，海峡两岸(温州)大健康产业园平台进一步深 化温台在大健康产业领域的合作。活动现场新签约台资项目16个，场外签约项目12个，总投资额达 41.84亿元，涉及医疗健康、智能制造、健康食品等领域。 两岸青年交流是本次活动的重点之一。启动仪式现场，温州支持台青发展政策正式发布，内容涵盖创业 扶持、就业指导、生活保障等八方面措施，为在温台青提供了更多发展机遇和服务保障。现场邀请了多 位在温创业就业的优秀台青代表，分享在温创业就业感悟，讲述两岸青年在温同心同行、携手打拼的精 彩 ...

Core Viewpoint - The article emphasizes the importance of optimizing the business environment in the Lushi New District as a key driver for attracting investment and achieving high-quality development [1][3]. Group 1: Investment Attraction Strategies - Lushi New District focuses on a multi-faceted investment strategy, utilizing a combination of head enterprises, local businesses, and industry chain integration to enhance economic development [1][2]. - The district has successfully implemented a project for the production of 1 billion bottles of health drinks, showcasing a model of deep integration between leading enterprises and local businesses [1]. - The establishment of the Shandong Haichen Long-term Energy Integrated Zero-carbon Industrial Park aims to support the province's green and low-carbon development, with tailored solutions for project approval and execution [2]. Group 2: Project Implementation and Support - The district has streamlined approval processes and enhanced service efficiency, allowing projects to commence immediately upon landing, exemplified by the introduction of the fourth-generation diatomaceous inorganic mineral board project [2][3]. - The integration of resources from leading enterprises and local companies has led to the successful launch of multiple projects, including the Shen Pharmaceutical Heze project, which revitalizes idle facilities [2]. - The district plans to designate 2025 as the year for further optimizing the business environment, with a commitment to improving service quality and responsiveness to enterprise needs [3].